Headache News and Research

Latest Headache News and Research

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

King Pharmaceuticals, Inc. announced today that it has licensed from Merck Santé S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT® 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT® is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.

28 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

FDA files complaint against sandwich manufacturer; company allegedly failed to correct violations

The U.S. Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a complaint for permanent injunction against Rel's Foods Inc. (Rel's), of Oakland, Calif., seeking to stop the company from manufacturing, producing, and selling adulterated food products.

27 Oct 2009

FDA approves Berinert for adults and adolescents with HAE

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

27 Oct 2009

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery.

27 Oct 2009

Dey Pharma launches EpiPen Auto-Injector

Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.

26 Oct 2009

Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting

Santarus, Inc., a specialty biopharmaceutical company, today announced that positive data from two investigator-initiated studies with ZEGERID® (omeprazole/sodium bicarbonate) will be presented in poster sessions at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting taking place in San Diego. These studies were supported by grants from Santarus.

26 Oct 2009

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

Surgery offers hope for migraine sufferers

In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.

26 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

Philippines calls for help to address disease outbreak in storms' aftermath

The WHO on Thursday said the Philippines is requesting "international help to fight a deadly outbreak of an infectious disease following two devastating tropical storms," Agence France-Presse reports. Parts of Manila, which are still flooded almost four weeks after Tropical Storm Ketsana hit, are experiencing an outbreak of the bacterial infection, leptospirosis (10/22).

24 Oct 2009

Tips to prevent allergy during Halloween

The haunted happenings of Halloween are upon us and soon we'll be carving pumpkins, dressing in costumes and telling spooky stories. But if your child has a food allergy, what's at the bottom of his or her trick-or-treat bag may be more frightening than any ghost or goblin.

23 Oct 2009

MedImmune announces interim data from its live attenuated influenza vaccine studies

MedImmune announced today that interim data from human studies of its nasal spray vaccine for the 2009 novel Influenza A (H1N1) virus demonstrate a similar clinical profile in children and adults 2 to 49 years of age as previously studied seasonal formulations of the vaccine.

23 Oct 2009

Combination treatement for IVF patients may eliminate vaginal bleeding

A prospective, multi-center study demonstrated that in IVF (in vitro fertilization) cycles supplemented with once-daily dosing of Crinone® vaginal progesterone gel and Estrace® oral estrogen, vaginal bleeding is rare in patients who become pregnant. Bleeding does occur in approximately one-quarter of patients who do not become pregnant. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

23 Oct 2009

eHealthInsurance releases answers for FAQs on swine flu and their health insurance

eHealthInsurance (NASDAQ: EHTH) today released a list of answers to questions frequently asked from people concerned about the H1N1 virus (also called swine flu) and their health insurance, who have called into its Customer Care Center, which includes a call center staffed with licensed insurance agents. Getting answers to these questions is particularly important for high-risk individuals: pregnant women, children and seniors.

22 Oct 2009

Headache News and Research

Latest Headache News and Research

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

New data from efficacy study of CIMZIA in Crohn's disease patients presented

FDA files complaint against sandwich manufacturer; company allegedly failed to correct violations

FDA approves Berinert for adults and adolescents with HAE

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Dey Pharma launches EpiPen Auto-Injector

Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Surgery offers hope for migraine sufferers

Updated data on XL184 study in patients with glioblastoma multiforme presented

Philippines calls for help to address disease outbreak in storms' aftermath

Tips to prevent allergy during Halloween

MedImmune announces interim data from its live attenuated influenza vaccine studies

Combination treatement for IVF patients may eliminate vaginal bleeding

eHealthInsurance releases answers for FAQs on swine flu and their health insurance

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in